GlaxoSmithKline rated market perform by Leerink Swann

GlaxoSmithKline plc was rated market perform with a strong near-term earnings growth forecast by Leerink Swann & Co. analyst Andrew Oh. The analyst said the breadth of the company's pipeline is impressive, but because the uncertain quality of its pipeline and upcoming exclusivity losses will temper long-term growth, the company is fairly valued. GlaxoSmithKline closed down $0.40, or 0.84%, at $47.42 on Monday on volume of 553,900 shares versus a three-month trailing average of 1,067,450 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.